Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
APLIF APPILI THERAPEUTICS INC
0.0410.0000.00%
Close
02/03 16:00 ET
High
0.042
Open
0.042
Turnover
2.20K
Low
0.041
Pre Close
0.041
Volume
53.00K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Appili Appoints Gelhaus, Baran as Directors to Support ATi-1701 Program
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to Support the ATI-1701 Biodefense Vaccine Program
Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF)
Appili to Get US Patent for Antibiotic ATI-1501
Appili Announces Notice of Allowance From USPTO for ATI-1501 Patent
Appili Therapeutics Announces Notice of Allowance From the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
Anticipated new patent strengthens ATI-1501's potential position as a more convenient alternative treatment option for metronidazole prescriptions on the market. Appili Therapeutics Inc. (TSX:APLI, OTCQB:APLIF) (the
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~$14M of Funding
Appili Therapeutics GAAP EPS of -C$0.04
Appili Therapeutics Inc. (TSE:APL) to Post FY2023 Earnings of ($0.09) Per Share, Zacks Small Cap Forecasts
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Equities researchers at Zacks Small Cap boosted their FY2023 earnings estimates for shares of Appili Therapeutics in a note issued to investors on
Appili Therapeutics GAAP EPS of -$0.03 misses by $0.01
Appili Therapeutics press release (OTCQX:APLIF): Q1 GAAP EPS of -$0.03 misses by $0.01. As of June 30, 2022, the Company had cash and short-term investments of $5.55 million, compared to $6.66 mill
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the first quarter of
Company Overview
More
Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. It focuses on building and advancing a diverse portfolio of anti-infective programs such as ATI-1501, ATI-1503, and ATI-1701. The company was founded on May 7, 2015 and is headquartered in Halifax, Canada.
CEO： Mr. Armand Balboni
Market： Pink Market
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet